Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Investigators at Vanderbilt University Medical Center have identified a previously uncharacterized bacterial defense system in 

 that couples the pathogen's response to host iron restriction with its resistance to bacitracin, an antimicrobial produced by the gut commensal 

, describe a 6-component "Bce module" that may represent a potential therapeutic target in an organism for which treatment options remain limited.

"C diff evolved to sense both stressors independently and collectively," Martin Douglass, PhD, first author and postdoctoral fellow in the lab of senior author Eric Skaar, PhD, MPH, said in a statement.

Bce Module Drives Bacitracin Resistance in C Difficile

 is a leading cause of hospital-acquired infection in the United States, with more than 200,000 hospital-associated infections occurring annually, according to the study authors. People taking antibiotics, those recently hospitalized or living in a health care facility, and adults older than 65 years are at greatest risk. Treatment options remain limited. Using CRISPR mutagenesis in the CD196 strain, investigators characterized a genetic cluster encoding a 2-component sensor system (BceS and BceR), an adenosine triphosphate–binding cassette efflux pump (BceA and BceB), and an undecaprenyl pyrophosphatase (BacA2) that together mediate the response to bacitracin.

 impaired growth in the presence of bacitracin, while complementation restored growth. Bacitracin exposure increased transcription of 

 more than 1000-fold in wild-type bacteria, an effect that was dependent on BceS and BceR. Investigators noted that this represents, to their knowledge, the first description of a Bce module that has incorporated an undecaprenyl pyrophosphatase as an accessory component.

Iron Restriction Increases C Difficile Susceptibility to Bacitracin

The investigators also found that expression of the module is repressed by Fur, the bacterium's principal iron-responsive transcriptional regulator. Because host neutrophils deploy the metal-sequestering protein calprotectin as part of nutritional immunity during infection, iron-limited conditions relieved Fur repression and increased transcription of the module independent of bacitracin exposure.

Liquid chromatography–mass spectrometry showed that iron chelation reduced undecaprenyl phosphate levels by approximately 50%. Because iron-dependent enzymes contribute to synthesis of this lipid carrier, the authors proposed that iron starvation reduces the available carrier pool and increases 

 susceptibility to bacitracin, which targets undecaprenyl pyrophosphate and interferes with carrier recycling during cell wall synthesis.

Investigators reported that bacitracin and iron chelation produced additive or synergistic growth defects in wild-type bacteria, with a greater effect observed in phosphatase-deficient mutants. The findings support a model in which low iron and bacitracin act as independent but converging stressors on cell envelope maintenance.

Bacitracin Clears Bce Module-Deficient C Difficile in Mouse Model

In a cefoperazone-treated mouse model of 

 infection, bacitracin administered in drinking water reduced fecal bacterial burden and protected against weight loss and mortality in mice infected with wild-type spores, though it did not clear the infection. In mice infected with a mutant lacking both 

, bacitracin treatment resulted in undetectable bacterial burden and complete survival.

The investigators concluded that the Bce module helps wild-type 

 withstand bacitracin exposure that would otherwise be more detrimental to the pathogen, positioning the module as a potential target for adjunctive therapy.

Douglass and colleagues described the Bce module as "an attractive therapeutic target," reasoning that inhibiting it could restore bacitracin sensitivity and allow the antibiotic to both neutralize the pathogen and clear infection.

 has been identified in human fecal samples and has shown activity against 

 in prior work, including preservation of gut microbiota during vancomycin treatment and reduction of antibiotic-associated diarrhea in separate trials. However, bacitracin production or quantification in the human gut itself has not been directly measured. Douglass suggested 

 could be explored as a probiotic option for patients at elevated risk for infection, and that agents targeting the newly identified system might eventually be developed for use alongside the bacterium.

Strain-Specific Findings Raise Generalizability Questions

The described mechanism was characterized primarily in a single 

 strain (CD196), and the investigators noted that transposon sequencing data from a different strain (R20291) suggested differences in cell envelope maintenance between strains, which may limit generalizability. Whether inhibiting the Bce module is feasible as a druggable strategy, and how BacA2 physically interacts with the sensor-transporter complex, remain unresolved questions for future study.

Douglass MV, Melton LR, Calcutt MW, et al. 

 couples responses to host nutritional immunity and a commensal-derived antibiotic to enable growth in the gut. 

. 2026;19(954). doi:10.1126/scisignal.aef8846

C diff coordinates threat response to survive in gut. News release. Vanderbilt University Medical Center; September 8, 2026

Articles

A newly defined six-component Bce defense module in *Clostridioides difficile* links host nutritional immunity to resistance against bacitracin produced by commensal *Bacillus licheniformis*. The BceSR two-component system induces the BceAB efflux pump and accessory phosphatase BacA2, enabling growth under bacitracin stress. Iron limitation relieves Fur repression, reduces undecaprenyl phosphate pools, and heightens bacitracin susceptibility, creating convergent envelope stress. In mice, bacitracin cleared infection only when key module genes were deleted, suggesting a druggable adjunctive target. Strain variability and in situ bacitracin levels remain important translational uncertainties.

Martin Douglass, PhD, and Vanderbilt colleagues found a Bce module that helps C diff evade bacitracin and host iron restriction

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

C Difficile Infection

C. difficile condition center page, resources on the topics of medical news and expert insight into Clostridium difficile can be found. Content includes articles, interviews, videos, podcasts, and breaking news on C. diff research, treatment, and drug development.

C Diff Resistance to Bacitracin Reveals Potential Drug Target

Michael Wechsler, MD, of National Jewish Health.

Beyond its efficacy signal, verekitug's extended dosing interval may offer a meaningful quality of life advantage for patients with severe 

, who often manage multiple injectable therapies. In the phase 2 VALIANT trial, presented at the 

European Respiratory Society (ERS) Congress 2026

, the every 12 week dosing arm delivered the strongest reduction in exacerbations among the 3 regimens tested.

"I think if you talk to patients, most patients would prefer to take a drug 4 times a year as opposed to 12 times a year or 13 times a year," Michael Wechsler, MD, MMSc, professor of medicine and director of the Cohen Family Asthma Institute at National Jewish Health, said in an interview with 

Verekitug's Quarterly Dosing Cuts Asthma Burden, With Michael Wechsler, MD

Why Less Frequent Dosing Matters to Patients

Wechsler said the appeal of quarterly dosing goes beyond convenience. Reducing the frequency of injections may also ease the day to day burden of living with a chronic disease. "Every 3 months, it's a little bit out of mind, and they're not worrying about their disease. And who likes to get injections?" he said. Combined with the strongest exacerbation reduction seen in the 100 mg every 12 week arm, Wechsler said the dosing schedule adds a practical advantage on top of the efficacy findings.

VALIANT's safety results were consistent with the existing biologic landscape in asthma. Adverse events occurred in 65% of the placebo group compared with 58% to 62% across the 3 verekitug dose arms. Most adverse events, including nasopharyngitis, headache, and bronchitis, were mild, with no grade 3 or higher events reported. A high rate of anti-drug antibodies was observed but did not appear to affect safety or efficacy outcomes.

Looking Ahead in Type 2 Inflammatory Disease

Verekitug has also shown efficacy in the phase 2 VIBRANT trial in CRSwNP, and Upstream Bio has said it plans to advance the therapy into phase 3 trials in both severe asthma and CRSwNP. Wechsler pointed to the broader trajectory of the field, noting that 7 biologic therapies for type 2 inflammatory disease are now FDA approved, with more in development. "This is an exciting time to be seeing patients with asthma, seeing patients with COPD, and patients with type 2 inflammation," he said. "I'm looking forward to a time when we can actually achieve the ultimate goal in asthma management, that's a cure, getting people into remission and having a sustained remission."

Verekitug Reduces Asthma Exacerbations Up to 87%, With Michael Wechsler, MD

Editor's Note: Wechsler reports relevant disclosures with Upstream Bio.

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma. GlobeNewswire. February 11, 2026. 

https://www.globenewswire.com/news-release/2026/02/11/3236073/0/en/Upstream-Bio-Reports-Positive-Top-line-Results-from-the-Phase-2-VALIANT-Trial-of-Verekitug-for-the-Treatment-of-Severe-Asthma.html

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026. GlobeNewswire. September 8, 2026. 

https://www.globenewswire.com/news-release/2026/09/08/3357341/0/en/upstream-bio-presents-results-from-the-phase-2-valiant-trial-of-verekitug-for-the-treatment-of-severe-asthma-in-oral-presentation-at-ers-congress-2026.html

Videos

Wechsler discusses why less frequent dosing matters to patients with severe asthma, plus VALIANT's safety profile and what's next for the field.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, used with the BF-RhodoLED lamp series, is FDA approved for actinic keratosis and, as of this approval, superficial basal cell carcinoma (sBCC) in adults.

How does Ameluz photodynamic therapy work? 

The topical gel is applied to the lesion and then activated with red light from the RhodoLED lamp, triggering a photodynamic reaction that selectively destroys the targeted lesion cells without surgery.

Among 187 adults with histologically confirmed sBCC, 66% of patients treated with Ameluz PDT achieved the composite primary endpoint of clinical and histological complete response at 12 weeks, compared with 5% treated with placebo-PDT.

 has approved Biofrontera's supplemental new drug application for Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, used with the BF-RhodoLED lamp series, for the treatment of 

The September 14 approval by the FDA makes Ameluz photodynamic therapy (PDT) the first and only PDT regimen cleared by the agency to treat a skin cancer. It is also now the only topical PDT in the United States indicated for both a precancerous lesion, actinic keratosis, and a skin malignancy.¹

“This approval reflects years of disciplined investment in the clinical development of Ameluz, and the latest stage in the ongoing expansion of our PDT platform,” Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera, said in a statement.¹ “We are planning an official launch of the sBCC indication late in the fourth quarter of 2026 through the first quarter of 2027 with our existing commercial organization and installed lamp base.”

Basal cell carcinoma is the most common skin cancer diagnosed within the US, with an estimated 3.6 million cases annually, of which the superficial subtype accounts for roughly 15% - 20%, or 540,000 to 720,000 diagnoses each year.¹,² Such lesions can extend several centimeters in diameter, frequently arise on the trunk and extremities, and often present as multiple lesions, a pattern for which nonsurgical, tissue-sparing options have remained limited.¹

Which Data Supported the Ameluz Treatment’s sBCC Approval?

The approval resulted from a multicenter, randomized, double-blind, vehicle-controlled phase 3 analysis involving 187 adult patients showing histologically confirmed sBCC.¹ The trial’s primary endpoint, a composite of clinical and histological complete response of a main target lesion 12 weeks after the final PDT cycle, was met by 66% of those on Ameluz PDT (95 of 145) compared with 5% given placebo-PDT (2 of 42).¹

Both histological clearance and complete clinical clearance of all target lesions followed a similar pattern, reaching 76% and 83% with Ameluz PDT versus 19% and 21% with placebo, respectively.¹ The most frequently reported adverse events observed by the investigative team were application-site reactions consistent with Ameluz's known safety profile.¹

How Does This Approval Expand Ameluz's Use in Dermatology?

Ameluz was previously approved only for actinic keratosis, and the sBCC indication broadens its addressable population using the same topical gel and red-light lamp platform, without requiring a new device.¹ Company leadership described the expansion as a growth driver for existing customers and an incentive for new practices to adopt the RhodoLED platform, while a dermatologist involved in the phase 3 program called it a rigorously studied, in-office alternative for patients with multiple lesions or tumors in cosmetically sensitive areas.¹

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools.

Biofrontera Inc. Biofrontera announces FDA approval of Ameluz Red Light PDT for the treatment of superficial basal cell carcinoma. Published September 14, 2026. Accessed September 14, 2026. 

https://www.globenewswire.com/news-release/2026/09/14/3361199/0/en/biofrontera-announces-fda-approval-of-ameluz-red-light-pdt-for-the-treatment-of-superficial-basal-cell-carcinoma.html

Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. 

FDA approval expands aminolevulinic acid 10% gel (Ameluz) used with the BF-RhodoLED red-light lamp series to include adult superficial basal cell carcinoma, establishing the first FDA-cleared photodynamic therapy regimen for a skin cancer. The indication leverages an existing topical-and-device platform already used for actinic keratosis, positioning it as a tissue-sparing, in-office option for patients with multiple lesions or cosmetically sensitive sites. Pivotal phase 3 data demonstrated markedly higher composite clinical/histologic complete response versus vehicle, with expected application-site reactions.

Ameluz is now the first FDA-approved photodynamic therapy for a skin cancer, expanding use to superficial basal cell carcinoma (sBCC) in adults.

FDA News

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Ameluz Treatment Becomes First FDA-Approved PDT for Skin Cancer


Zasocitinib is under FDA priority review for adults with moderate-to-severe plaque psoriasis, based on phase 3 data from the LATITUDE PsO program.


Zasocitinib is an oral, highly selective TYK2 inhibitor that blocks IL-23 and other core inflammatory pathways involved in psoriasis without affecting JAK1, 2, or 3 signaling.


Both LATITUDE PsO 3001 and 3002 met their co-primary endpoints at week 16, with roughly 70% to 76% of zasocitinib-treated patients achieving sPGA 0/1 or PASI 75, respectively, versus placebo and apremilast.

 has accepted Takeda's new drug application under priority review for zasocitinib, an oral tyrosine kinase 2 (TYK2) inhibitor for adult patients living with moderate-to-severe 

, based on phase 3 data spanning nearly 3000 individuals.¹

A Prescription Drug User Fee Act (PDUFA) target action date is slated for the first quarter of 2027.¹ The filing rests on the phase 3 LATITUDE PsO 3001 and 3002 trials, supported by long-term findings resulting from the open-label LATITUDE PsO 3003 study.¹ The European Medicines Agency (EMA) has also separately accepted a marketing application for zasocitinib, resulting in a parallel EU review.¹

"Based on results across nearly 3000 patients, zasocitinib has the potential to be a leading oral treatment option in psoriasis," Andy Plump, MD, PhD, president of research and development at Takeda, said in a statement.

Zasocitinib Phase 3 Efficacy in Moderate-to-Severe Psoriasis

During the phase 3 LATITUDE PsO 3001 (NCT06088043) and 3002 (NCT06108544) trials, researchers randomized 693 and 1108 adult patients living with moderate-to-severe psoriasis across 21 countries to zasocitinib, placebo, or apremilast in a double-blind design. They met both co-primary endpoints at Week 16.² A static Physician Global Assessment (sPGA) score of 0 or 1 was attained by 71% and 69% of zasocitinib-treated subjects across the pair of trials, versus 11% and 13% on placebo and 32% and 30% on apremilast (

Psoriasis Area and Severity Index 75 (PASI 75) responses reached 76% and 71% with zasocitinib, compared with 12% for placebo and 37% and 33% for apremilast (

 <.001 for each).² Clearance appeared by Week 4 and continued through Week 52.¹

Zasocitinib Safety Results and High-Impact Site Clearance

Complete clearance rates also favored zasocitinib, with PASI 90 being attained by 61% and 52% of patients across the two trials, versus single-digit placebo rates (

<.001 for each).² High-impact, hard-to-treat sites responded as well, including scalp-specific PGA 0/1 rates of 74% to 77% (

Zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies and a lack of new safety signals, according to Takeda’s release.¹ Adverse events (AEs) in at least 5% of patients across both trials included upper respiratory tract infection (10.1%), nasopharyngitis (6.2%), and acne (6.5%).¹

The company also highlighted its studying of zasocitinib in phase 3 psoriatic arthritis research and phase 2 programs spanning vitiligo, Crohn's disease, ulcerative colitis, and hidradenitis suppurativa.¹

Takeda. U.S. FDA accepts new drug application under priority review for Takeda's zasocitinib in moderate-to-severe plaque psoriasis. Published September 14, 2026. Accessed September 14, 2026. 

https://www.takeda.com/newsroom/newsreleases/2026/fda-priority-review-zasocitinib-psoriasis/

Armstrong AW, Gooderham M, Lynde C, et al. Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: a randomized clinical trial. JAMA Dermatol. 2024;160(10):1066-1074. doi:10.1001/jamadermatol.2024.2701.

FDA priority review has been granted for Takeda’s zasocitinib, an oral TYK2 inhibitor for adults with moderate-to-severe plaque psoriasis, supported by phase 3 LATITUDE PsO 3001/3002 and long-term open-label 3003 data totaling nearly 3000 patients. A PDUFA action is targeted for Q1 2027, with a parallel EMA review underway. At Week 16, zasocitinib achieved robust sPGA 0/1 and PASI responses versus placebo and apremilast, with early onset and durability to Week 52, and no new safety signals.

Phase 3 data show zasocitinib use led to clear or almost clear skin in around 70% of patients by Week 16, setting up an FDA decision in early 2027.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

FDA Priority Review Granted to Zasocitinib for Moderate to Severe Psoriasis 

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Anjali Owens, MD | Image Credit: Penn Medicine

EDG-7500 has displayed clinically meaningful improvements in patients with 

 after 12 weeks, according to results from the CIRRUS-HCM trial.

European Society of Cardiology (ESC) Congress 2026

 in Munich, Germany, by Anjali Owens, MD, a cardiovascular fellow at the Hospital of the University of Pennsylvania.

“The totality of the Phase 2 efficacy and tolerability data continues to support a differentiated profile for EDG-7500 across HCM,” Matthew Martinez, MD, president of the HCM Society, said in a statement. “What is especially encouraging is the consistency of symptom and functional improvement across dose levels without evidence of systolic liability or heart failure risk.”

EDG-7500 is a novel cardiac sarcomere modulator in development by Edgewise Therapeutics, Inc., for hypertrophic cardiomyopathy (HCM). Preclinical models have shown increases in early diastolic relaxation while maintaining myosin availability, as well as reductions in LVOT gradients and preservation of net systolic function. However, no meaningful reductions in left ventricular ejection fraction (LVEF) have been shown in the EDG-7500 program prior to this trial.

CIRRUS-HCM is an ongoing open-label study conducted across 17 locations in the US. Patients were eligible for inclusion if they were ≥18 to <85 years of age and were diagnosed with HCM at the time of screening. Additionally, patients were required to have an LVOT peak gradient ≥50 mmHg measured at rest or during the Valsalva maneuver, or LVOT peak gradient <30 mmHg measured at rest and <50 mmHg during the Valsalva maneuver, among other criteria. Patients who had undergone invasive septal reduction therapy, had obstructive coronary artery disease, or a documented history of myocardial infarction, among other criteria, were excluded.

Patients were randomly assigned to 1 of 4 experimental groups: the first group, Part A, received a single dose of EDG-7500; Part B included patients with obstructive HCM who received EDG-7500 once daily for ≤28 days; Part C included patients with nonobstructive HCM and received EDG-7500 once daily; and Part D received EDG-7500 for ≤24 months. Part D included both new participants and patients who had completed part B or C.

CIRRUS’s primary outcome is incidence of treatment-emergent adverse events from screening through study completion – for Part A, this period is ≤38 days, while Part B and C were ≤73 days and Part D was ≤18 months. Secondary outcomes included change from baseline in LVOT gradient, pharmacokinetic parameters of EDG-7500, and change from baseline in cardiac biomarkers.

The presentation at ESC 2026 was a 12-week evaluation of the drug’s safety and efficacy. By 12 weeks, Owens and colleagues did not find any clinically meaningful change in LVEF. No patients exhibited reductions in LVEF to <50%, and no correlation was observed between EDG-7500 treatment and LVEF change. Additionally, patients with obstructive HCM did exhibit substantial reductions in LVOT gradient by 12 weeks, with Valsalva measurements falling by 51% from baseline and resting LVOT gradient falling by 55%. NT-proBNP exhibited a geometric mean decrease of 56% from baseline, while Hs-cTnl dropped by 40% from baseline.

Patients with obstructive HCM also displayed sustained improvements in New York Heart Association (NYHA) Class, with 70% of patients improving by ≥1 NYHA class by week 12 and 50% of patients in NYHA Class III improving to Class I by week 12. Patients with nonobstructive HCM also saw substantial improvements in NYHA class, with 29% in Class III improving to Class I and 64% of patients improving by ≥1 NYHA class at week 12. EDG-7500 also exhibited no LVEF <50% during these 12 weeks while remaining well-tolerated with 2 severe adverse treatment events, 1 of which was determined to be unrelated to treatment.

Ultimately, Owens and colleagues concluded that EDG-7500 has performed well in both disease populations over the 12 months of treatment thus far. In the presentation, Owens announced that phase 3 trials of EDG-7500 are on track to initiate by Q4 2026.

“From the outset, our goal was to identify a cardiovascular therapy with a profile that avoids the liability of the CMI class, with EDG-7500 emerging from that effort,” Kevin Koch, PhD, president and chief executive officer of Edgewise Therapeutics, said in a statement. “These Phase 2 data mark an important milestone for Edgewise and the HCM community, reinforcing EDG-7500’s unique approach with the potential to address diastolic dysfunction across HCM without meaningful impact on LVEF.”

Owens A. CIRRUS-HCM: 12-Week Evaluation of the Safety and Efficacy of the Novel Cardiac Sarcomere Modulator EDG-7500 in Nonobstructive and Obstructive Hypertrophic Cardiomyopathy. Presented at the European Society of Cardiology (ESC) Congress 2026, Munich, Germany. August 28-31, 2026.

Edgewise Therapeutics. Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM). 

. June 16, 2026. Accessed September 14, 2026. 

https://www.prnewswire.com/news-releases/edgewise-therapeutics-announces-positive-top-line-data-from-12-week-phase-2-cirrus-hcm-trial-with-edg-7500-in-obstructive-and-nonobstructive-hypertrophic-cardiomyopathy-hcm-302801108.html

Edgewise Therapeutics, Inc. A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM). ClinicalTrials.gov Identifier: NCT06347159. Updated July 31, 2026. Accessed September 11, 2026. 

https://clinicaltrials.gov/study/NCT06347159

EDG-7500, a novel cardiac sarcomere modulator, demonstrated 12-week safety and efficacy signals in both obstructive and nonobstructive hypertrophic cardiomyopathy within the open-label, multicenter CIRRUS-HCM program. Left ventricular systolic function appeared preserved, with no clinically meaningful LVEF decline and no patients falling below 50%. Obstructive disease showed marked LVOT gradient reductions and biomarker improvements (NT-proBNP, hs-cTnI), alongside meaningful NYHA class shifts. Overall tolerability was favorable, supporting planned Phase 3 initiation in Q4 2026.

The novel cardiac sarcomere modulator from Edgewise Therapeutics saw substantial improvements in both nonobstructive and obstructive HCM after 12 weeks.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Cardiomyopathy

CIRRUS-HCM: EDG-7500 Improves LVOT, NYHA Class in oHCM and nHCM

Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 1 Diabetes

FDA Clears Beta Bionics' Mint Insulin Patch Pump for Diabetes

Effective EoE care requires a treatment plan that works for both the disease and the patient. The expert faculty explore how individualized treatment selection and appropriately timed reassessment can support sustained disease control.

Video Series

Personalizing Treatment and Reassessment in EoE

Achieving remission is only one phase of EoE care. The panel explores how induction and maintenance therapies can work together to control inflammation and sustain disease control over time.

Induction and Maintenance Therapies in EoE

Guy Brusselle, MD, PhD, of Ghent University Hospital.

Guy Brusselle, MD, PhD, explains why broader cytokine blockade with dupilumab outpaced omalizumab, and why nonremitters in EVEREST still improved.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Dupilumab's IL-4/IL-13 Blockade Drives Efficacy Edge in EVEREST

Adam Friedman, MD, breaks down how to say no strategically in dermatology, from delaying an answer to sharing the decision with the requester.

Q&A: Why Saying 'No' is a Career Skill as a Clinician, with Adam Friedman, MD

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

As ragweed and mold drive this year's fall symptom surge, updated GRADE recommendations shift first-line therapy toward combination intranasal treatment.

Seasonal Allergy

FAQ: Treating Fall Allergic Rhinitis Under The 2026 ARIA-EAACI Update

Stay updated with the latest healthcare breakthroughs, including a new ablation catheter for AFib and progress in the hereditary angioedema pipeline.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

The HCPFive: Top News for Healthcare Providers from the Week of 09/06

Robert Giugliano, MD, is a senior investigator with the TIMI Study Group, staff physician in the Cardiovascular Division at Brigham and Womenâ€™s Hospital, and associate professor of medicine at Harvard Medical School. Dr. Giuglianoâ€™s areas of research interest include novel antithrombotic, fibrinolytic agents, and lipid-lowering therapies, and patient outcomes following Acute Coronary Syndromes. He has authored more than 200 articles and chapters, and delivered hundreds of lectures. Dr. Giugliano is the principal investigator for the ENGAGE-AF TIMI 48 trial, and a member of the Operations Committees and lead TIMI investigator for the IMPROVE-IT, FOURIER, and EARLY ACS trials. 

Robert Giugliano, MD, breaks down his prespecified subanalysis of the VESALIUS-CV trial, evaluating evolocumab’s effect on cardiovascular mortality.

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Evolocumab Improves Survival in Patients Without Prior MI or Stroke

Phase 2 VALIANT data show the anti-TSLP receptor antibody sharply reduced exacerbations in patients with high eosinophil counts.

Kristina Duffin, MD, MS is a professor in the Department of Dermatology and recently appointed Dean of the Spencer Fox Eccles School of Medicine at the University of Utah.

Kristina Duffin, MD, dean of the Spencer Fox Eccles School of Medicine, discusses leadership, delegation, and coaching at LEADderm 2026.

Latest News

C Diff Resistance to Bacitracin Reveals Potential Drug Target

Verekitug's Quarterly Dosing Cuts Asthma Burden, With Michael Wechsler, MD

Ameluz Treatment Becomes First FDA-Approved PDT for Skin Cancer

FDA Priority Review Granted to Zasocitinib for Moderate to Severe Psoriasis

CIRRUS-HCM: EDG-7500 Improves LVOT, NYHA Class in oHCM and nHCM